08HH.STU Shanghai Fosun Pharmaceutical (Group) Co. Ltd

Healthcare Pharmaceuticals Stuttgart Exchange
9.01 EUR
Close of Nov 3, 2026
1.33 2.44
Market cap
EUR 4.97B
P/E
11.0x
P/B
0.72x
ROE
7.1%
Dividend yield
2.72%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 08HH.STU undervalued?

Graham number
Price9.01
Graham value15.13
Discount40.5%

08HH.STU trades 40.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Shanghai Fosun Pharmaceutical (Group) Co. Ltd fundamental analysis

No fundamental analysis for Shanghai Fosun Pharmaceutical (Group) Co. Ltd yet.

Shanghai Fosun Pharmaceutical (Group) Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Shanghai Fosun Pharmaceutical (Group) Co. Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company's product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural …

Full company profile